Teva slumps after Express Scripts funds migraine rivals in USA major prescription benefit manager in the US will not reimburse Teva’s preventative migraine drug Ajovy (fremanezumab), in Share XTeva slumps after Express Scripts funds migraine rivals in UShttps://pharmaphorum.com/news/teva-slumps-after-express-scripts-funds-migraine-rivals-in-us/
Sophia Genetics unveils latest ‘genome browser’ softwareThe Swiss medical data firm Sophia Genetics has launched the latest iteration of its “genome browser” software, which Share XSophia Genetics unveils latest ‘genome browser’ softwarehttps://pharmaphorum.com/news/sophia-genetics-unveils-latest-genome-browser-software/
J&J preps for FDA panel grilling over depression drugJohnson & Johnson is “confident” about regulatory reviews of its depression drug esketamine ahead of a likely grilling Share XJ&J preps for FDA panel grilling over depression drughttps://pharmaphorum.com/news/janssen-preps-for-fda-panel-grilling-esketamine/
AI could transform care for older people, robot tells MPsA House of Commons committee questioned a humanoid robot, Pepper, to see how artificial intelligence (AI) and robotics Share XAI could transform care for older people, robot tells MPshttps://pharmaphorum.com/news/ai-could-transform-care-for-older-people-robot-tells-mps/
US blood pressure drug price doubles following shortagesPrices of the generic blood pressure drug valsartan rose more than any other in the US following a Share XUS blood pressure drug price doubles following shortageshttps://pharmaphorum.com/news/us-blood-pressure-drug-price-doubles-following-shortages/
Roche beats revenue forecasts as sales of old drugs take off in ChinaRoche has beaten analysts’ revenue forecasts in the third quarter, after mounting sales of its older drugs in Share XRoche beats revenue forecasts as sales of old drugs take off in Chinahttps://pharmaphorum.com/news/roche-beats-revenue-forecasts-as-sales-of-old-drugs-take-off-in-china/
Balancing expectations: An unmet need in the orphan disease arenaThere are between 6000 and 8000 rare diseases in the world, and one in ten people in Europe Share XBalancing expectations: An unmet need in the orphan disease arenahttps://pharmaphorum.com/views-analysis-market-access/balancing-expectations-rare-disease-arena/
Pfizer’s Talzenna PARP breast cancer drug approved in USThe US drug regulator has approved Pfizer’s breast cancer medicine Talzenna (talazoparib) for patients with a certain mutation. Share XPfizer’s Talzenna PARP breast cancer drug approved in UShttps://pharmaphorum.com/news/pfizers-talzenna-parp-breast-cancer-drug-approved-in-us/
Samsung Bioepis’ Humira biosimilar launches in EUSamsung Bioepis has become the latest biosimilars company to confirm it has launched a cheaper near-copy of AbbVie’s Share XSamsung Bioepis’ Humira biosimilar launches in EUhttps://pharmaphorum.com/news/samsung-bioepis-humira-biosimilar-launches-in-eu/
Sanofi/Regeneron’s Dupixent could be first biologic approved for nasal polypsTrials of Sanofi and Regeneron’s drug Dupixent (dupilumab) have shown positive results for treating patients suffering from chronic Share XSanofi/Regeneron’s Dupixent could be first biologic approved for nasal polypshttps://pharmaphorum.com/news/sanofi-regenerons-dupixent-could-be-first-biologic-approved-for-nasal-polyps/
Roche and SQZ expand cell therapy deal to more than $1.3bnUS biotech SQZ Biotechnologies has expanded a collaboration with Roche to develop cancer therapies based on antigen presenting Share XRoche and SQZ expand cell therapy deal to more than $1.3bnhttps://pharmaphorum.com/news/roche-and-sqz-expand-cell-therapy-deal-to-more-than-1-3bn/
Billions up for grabs as EU patent on AbbVie’s Humira expiresThe patent for Humira, the world’s bestselling drug, expires in Europe today – opening the door for a Share XBillions up for grabs as EU patent on AbbVie’s Humira expireshttps://pharmaphorum.com/news/billions-up-for-grabs-as-eu-patent-abbvies-humira-expires/
Sensyne’s gestational diabetes AI app launches on the NHSArtificial intelligence company Sensyne Health has launched a new app that helps women manage gestational diabetes, and five Share XSensyne’s gestational diabetes AI app launches on the NHShttps://pharmaphorum.com/news/sensynes-gestational-diabetes-ai-app-launches-on-the-nhs/
AZ to continue with investment freeze following ‘no deal’ BrexitAstraZeneca will keep manufacturing investments in Britain on hold if the UK’s negotiations with Brussels fail to provide Share XAZ to continue with investment freeze following ‘no deal’ Brexithttps://pharmaphorum.com/news/az-to-continue-with-investment-freeze-following-no-deal-brexit/
Novartis challenges court ruling allowing use of Avastin in wet AMDNovartis is appealing against a High Court ruling that it is lawful for the NHS to prescribe Roche’s Share XNovartis challenges court ruling allowing use of Avastin in wet AMDhttps://pharmaphorum.com/news/novartis-challenges-court-ruling-allowing-use-of-avastin-in-wet-amd/
Deep Lens unveils cancer diagnosis AI tech for pathologistsDigital pathology startup Deep Lens has unveiled an artificial intelligence (AI) platform that will enable pathologists to diagnose Share XDeep Lens unveils cancer diagnosis AI tech for pathologistshttps://pharmaphorum.com/news/deep-lens-unveils-cancer-diagnosis-ai-tech-for-pathologists/
Novo Nordisk poaches AZ’s Helfgott to run Biopharm businessNovo Nordisk has poached a top executive from AstraZeneca, tasking Ludovic Helfgott to lead development of its haemophilia Share XNovo Nordisk poaches AZ’s Helfgott to run Biopharm businesshttps://pharmaphorum.com/news/novo-nordisk-poaches-azs-helfgott-to-run-biopharm-business/
Merck KGaA’s BTK drug reduces lesions in relapsing MS patientsGermany’s Merck KGaA has said it is “encouraged” by mid-stage trial results showing that its Bruton’s kinase (BTK) Share XMerck KGaA’s BTK drug reduces lesions in relapsing MS patientshttps://pharmaphorum.com/news/merck-kgaas-btk-drug-reduces-lesions-in-relapsing-ms-patients/
An Interview with Alexander Zuern, Device Testing Manager, from Novartis Share XAn Interview with Alexander Zuern, Device Testing Manager, from Novartishttps://pharmaphorum.com/partner-content/an-interview-with-alexander-zuern-device-testing-manager-from-novartis/
Preliminary Attendee List Released for Orphan Drugs & Rare Diseases Conference Share XPreliminary Attendee List Released for Orphan Drugs & Rare Diseases Conferencehttps://pharmaphorum.com/partner-content/preliminary-attendee-list-released-for-orphan-drugs-rare-diseases-conference/
Spotlight sessions at the upcoming Lyophilization USA Conference Share XSpotlight sessions at the upcoming Lyophilization USA Conferencehttps://pharmaphorum.com/partner-content/spotlight-sessions-at-the-upcoming-lyophilization-usa-conference/
SMi’s release speaker interview Anita Burrell, speaker at Biosimilars USA Share XSMi’s release speaker interview Anita Burrell, speaker at Biosimilars USAhttps://pharmaphorum.com/partner-content/smis-release-speaker-interview-anita-burrell-speaker-at-biosimilars-usa/
Carina Schey, University of Groningen, Orphan Drugs & Rare Diseases Chair Invitation Share XCarina Schey, University of Groningen, Orphan Drugs & Rare Diseases Chair Invitationhttps://pharmaphorum.com/partner-content/carina-schey-university-of-groningen-orphan-drugs-rare-diseases-chair-invitation/
Corporate Communications chief of Astellas, Jo Taylor moves to Cello Health Communications Share XCorporate Communications chief of Astellas, Jo Taylor moves to Cello Health Communicationshttps://pharmaphorum.com/partner-content/corporate-communications-chief-of-astellas-jo-taylor-moves-to-cello-health-communications/
